aidsmap news story
A once-weekly single-tablet regimen containing islatravir and lenacapavir maintained viral suppression in people with HIV who switched from standard daily oral treatment, according to a pair of studies presented at AIDS 2026.
Merck’s islatravir is the first nucleoside reverse transcriptase translocation inhibitor, which interferes with the HIV enzyme in a different way than familiar nucleoside/nucleotide reverse transcriptase inhibitors. A once-daily pill combining islatravir and doravirine, sold as Idvynso, was approved in the US in April.
Lenacapavir, from Gilead Sciences, is the first HIV capsid inhibitor. A twice-yearly injectable formulation, sold as Sunlenca, was approved in 2022 as a component of combination therapy for people with multidrug-resistant HIV. Injectable lenacapavir alone, sold as Yeztugo, was approved for PrEP last year. Lenacapavir also comes in a pill form, which is used as part of an initial loading dose before injections.
Read the full news story here.
View all aidsmap reports from AIDS 2026
Source : aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.